Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

This study has been completed.
Information provided by (Responsible Party):
Mirati Therapeutics Inc. Identifier:
First received: May 14, 2008
Last updated: January 6, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)